Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2012

01-12-2012

TGF-β signalling and its role in cancer progression and metastasis

Authors: Yvette Drabsch, Peter ten Dijke

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Login to get access

Abstract

The transforming growth factor-β (TGF-β) system signals via protein kinase receptors and SMAD mediators to regulate a large number of biological processes. Alterations of the TGF-β signalling pathway are implicated in human cancer. Prior to tumour initiation and early during progression, TGF-β acts as a tumour suppressor; however, at later stages, it is often a tumour promoter. Knowledge about the mechanisms involved in TGF-β signal transduction has allowed a better understanding of cancer progression, invasion, metastasis and epithelial-to-mesenchymal transition. Furthermore, several molecular targets with great potential in therapeutic interventions have been identified. This review discusses the TGF-β signalling pathway, its involvement in cancer and current therapeutic approaches.
Literature
1.
Frolik, C. A., Dart, L. L., Meyers, C. A., Smith, D. M., & Sporn, M. B. (1983). Purification and initial characterization of a type β transforming growth factor from human placenta. Proceedings of the National Academy of Sciences of the United States of America, 80(12), 3676–3680.PubMed
2.
Galat, A. (2011). Common structural traits for cystine knot domain of the TGF-β superfamily of proteins and three-fingered ectodomain of their cellular receptors. Cellular and Molecular Life Sciences: CMLS, 68(20), 3437–3451.PubMed
3.
Roberts, A. B. (1998). Molecular and cell biology of TGF-β. Mineral and Electrolyte Metabolism, 24(2–3), 111–119.PubMed
4.
Govinden, R., & Bhoola, K. D. (2003). Genealogy, expression, and cellular function of transforming growth factor-β. Pharmacology & Therapeutics, 98(2), 257–265.
5.
Funkenstein, B., Olekh, E., & Jakowlew, S. B. (2010). Identification of a novel transforming growth factor-β (TGF-β6) gene in fish: regulation in skeletal muscle by nutritional state. BMC Molecular Biology, 11, 37.PubMed
6.
Rider, C. C., & Mulloy, B. (2010). Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. The Biochemical Journal, 429(1), 1–12.PubMed
7.
Miyazono, K., Kamiya, Y., & Morikawa, M. (2010). Bone morphogenetic protein receptors and signal transduction. Journal of Biochemistry, 147(1), 35–51.PubMed
8.
Schier, A. F. (2009). Nodal morphogens. Perspectives in Biology, 1(5), a003459.PubMed
9.
Kumar, A., Lualdi, M., Lewandoski, M., & Kuehn, M. R. (2008). Broad mesodermal and endodermal deletion of nodal at postgastrulation stages results solely in left/right axial defects. Developmental Dynamics, 237(12), 3591–3601.PubMed
10.
Lee, J. D., Migeotte, I., & Anderson, K. V. (2010). Left–right patterning in the mouse requires EPB4.1l5-dependent morphogenesis of the node and midline. Developmental Biology, 346(2), 237–246.PubMed
11.
Lee, S. J. (1990). Identification of a novel member (GDF-1) of the transforming growth factor-β superfamily. Molecular Endocrinology, 4(7), 1034–1040.PubMed
12.
Moustakas, A., & Heldin, C. H. (2009). The regulation of TGF-β signal transduction. Development, 136(22), 3699–3714.PubMed
13.
Josso, N., Belville, C., di Clemente, N., & Picard, J. Y. (2005). AMH and AMH receptor defects in persistent Mullerian duct syndrome. Human Reproduction Update, 11(4), 351–356.PubMed
14.
di Clemente, N., & Belville, C. (2006). Anti-Mullerian hormone receptor defect. Clinical Endocrinology & Metabolism, 20(4), 599–610.
15.
Rosal-Goncalves, M., Almeida, C., Barber, J., Kay, T., Limbert, C., Lopes, L., et al. (2010). Mutation of the MIF type II receptor in two brothers. Journal of Pediatric Endocrinology & Metabolism: JPEM, 23(3), 315–317.
16.
Xia, Y., & Schneyer, A. L. (2009). The biology of activin: recent advances in structure, regulation and function. The Journal of Endocrinology, 202(1), 1–12.PubMed
17.
Aleman-Muench, G. R., & Soldevila, G. (2012). When versatility matters: activins/inhibins as key regulators of immunity. Immunology and Cell Biology, 90, 137–148.PubMed
18.
Stenvers, K. L., & Findlay, J. K. (2010). Inhibins: from reproductive hormones to tumor suppressors. Trends in Endocrinology and Metabolism, 21(3), 174–180.PubMed
19.
Tasaka, K., Kasahara, K., Masumoto, N., Mizuki, J., Fukami, K., Miyake, A., et al. (1994). Characterization of activin A-, activin AB- and activin B-responding cells by their responses to hypothalamic releasing hormones. Biochemical and Biophysical Research Communications, 203(3), 1739–1744.PubMed
20.
Shi, Y., & Massagué, J. (2003). Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell, 113(6), 685–700.PubMed
21.
Gatza, C. E., Oh, S. Y., & Blobe, G. C. (2010). Roles for the type III TGF-β receptor in human cancer. Cellular Signalling, 22(8), 1163–1174.PubMed
22.
Bernabeu, C., Lopez-Novoa, J. M., & Quintanilla, M. (2009). The emerging role of TGF-β superfamily coreceptors in cancer. Biochimica et Biophysica Acta, 1792(10), 954–973.PubMed
23.
Kang, J. S., Liu, C., & Derynck, R. (2009). New regulatory mechanisms of TGF-β receptor function. Trends in Cell Biology, 19(8), 385–394.PubMed
24.
Huminiecki, L., Goldovsky, L., Freilich, S., Moustakas, A., Ouzounis, C., & Heldin, C. H. (2009). Emergence, development and diversification of the TGF-β signalling pathway within the animal kingdom. BMC Evol Biol, 9, 28.PubMed
25.
Ross, S., & Hill, C. S. (2008). How the SMADs regulate transcription. The International Journal of Biochemistry & Cell Biology, 40(3), 383–408.
26.
Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L., & Wrana, J. L. (1998). SARA, a Fyve domain protein that recruits SMAD2 to the TGF-β receptor. Cell, 95(6), 779–791.PubMed
27.
Sflomos, G., Kostaras, E., Panopoulou, E., Pappas, N., Kyrkou, A., Politou, A. S., et al. (2011). ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN. Journal of Cell Science, 124(Pt 19), 3209–3222.PubMed
28.
Makkar, P., Metpally, R. P., Sangadala, S., & Reddy, B. V. (2009). Modeling and analysis of MH1 domain of SMADs and their interaction with promoter DNA sequence motif. Journal of Molecular Graphics & Modelling, 27(7), 803–812.
29.
Itoh, S., & ten Dijke, P. (2007). Negative regulation of TGF-β receptor/SMAD signal transduction. Current Opinion in Cell Biology, 19(2), 176–184.PubMed
30.
Hata, A., Lagna, G., Massagué, J., & Hemmati-Brivanlou, A. (1998). SMAD6 inhibits Bmp/SMAD1 signaling by specifically competing with the SMAD4 tumor suppressor. Genes & Development, 12(2), 186–197.
31.
Dennler, S., Huet, S., & Gauthier, J. M. (1999). A short amino-acid sequence in Mh1 domain is responsible for functional differences between SMAD2 and SMAD3. Oncogene, 18(8), 1643–1648.PubMed
32.
Derynck, R., & Akhurst, R. J. (2007). Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nature Cell Biology, 9(9), 1000–1004.PubMed
33.
Rifkin, D. B. (2005). Latent transforming growth factor-β (TGF-β) binding proteins: orchestrators of TGF-β availability. The Journal of Biological Chemistry, 280(9), 7409–7412.PubMed
34.
Kusakabe, M., Cheong, P. L., Nikfar, R., McLennan, I. S., & Koishi, K. (2008). The structure of the TGF-β latency associated peptide region determines the ability of the proprotein convertase furin to cleave TGF-β s. Journal of Cellular Biochemistry, 103(1), 311–320.PubMed
35.
Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F., & Wrana, J. L. (2003). Distinct endocytic pathways regulate TGF-β receptor signalling and turnover. Nature Cell Biology, 5(5), 410–421.PubMed
36.
Santibanez, J. F., Blanco, F. J., Garrido-Martin, E. M., Sanz-Rodriguez, F., del Pozo, M. A., & Bernabeu, C. (2008). Caveolin-1 interacts and cooperates with the transforming growth factor-β type I receptor Alk1 in endothelial caveolae. Cardiovascular Research, 77(4), 791–799.PubMed
37.
Zhang, Y. E. (2009). Non-SMAD pathways in TGF-β signaling. Cell Research, 19(1), 128–139.PubMed
38.
Sanchez-Elsner, T., Botella, L. M., Velasco, B., Corbi, A., Attisano, L., & Bernabeu, C. (2001). Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. The Journal of Biological Chemistry, 276(42), 38527–38535.PubMed
39.
Liu, F., & Matsuura, I. (2005). Inhibition of SMAD antiproliferative function by Cdk phosphorylation. Cell Cycle, 4(1), 63–66.PubMed
40.
Sherr, C. J., & Roberts, J. M. (1999). Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes & Development, 13(12), 1501–1512.
41.
Donovan, J., & Slingerland, J. (2000). Transforming growth factor-β and breast cancer: cell cycle arrest by transforming growth factor-β and its disruption in cancer. Breast Cancer Research, 2(2), 116–124.PubMed
42.
Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M., & Massagué, J. (1990). Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell, 62(1), 175–185.PubMed
43.
Slingerland, J. M., Hengst, L., Pan, C. H., Alexander, D., Stampfer, M. R., & Reed, S. I. (1994). A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Molecular and Cellular Biology, 14(6), 3683–3694.PubMed
44.
Geng, Y., & Weinberg, R. A. (1993). Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proceedings of the National Academy of Sciences of the United States of America, 90(21), 10315–10319.PubMed
45.
Massagué, J., Blain, S. W., & Lo, R. S. (2000). TGF-β signaling in growth control, cancer, and heritable disorders. Cell, 103(2), 295–309.PubMed
46.
Pardali, K., & Moustakas, A. (2007). Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochimica et Biophysica Acta, 1775(1), 21–62.PubMed
47.
Chen, C. R., Kang, Y., & Massagué, J. (2001). Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor β growth arrest program. Proceedings of the National Academy of Sciences of the United States of America, 98(3), 992–999.PubMed
48.
Chen, C. R., Kang, Y., Siegel, P. M., & Massagué, J. (2002). E2f4/5 and P107 as SMAD cofactors linking the TGF-β receptor to c-Myc repression. Cell, 110(1), 19–32.PubMed
49.
Frederick, J. P., Liberati, N. T., Waddell, D. S., Shi, Y., & Wang, X. F. (2004). Transforming growth factor β-mediated transcriptional repression of c-Myc is dependent on direct binding of SMAD3 to a novel repressive SMAD binding element. Molecular and Cellular Biology, 24(6), 2546–2559.PubMed
50.
Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., et al. (2002). c-myc is a downstream target of the SMAD pathway. The Journal of Biological Chemistry, 277(1), 854–861.PubMed
51.
Tachibana, I., Imoto, M., Adjei, P. N., Gores, G. J., Subramaniam, M., Spelsberg, T. C., et al. (1997). Overexpression of the TGF-β -regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. The Journal of Clinical Investigation, 99(10), 2365–2374.PubMed
52.
Jang, C. W., Chen, C. H., Chen, C. C., Chen, J. Y., Su, Y. H., & Chen, R. H. (2002). TGF-β induces apoptosis through SMAD-mediated expression of DAP-kinase. Nature Cell Biology, 4(1), 51–58.PubMed
53.
Valderrama-Carvajal, H., Cocolakis, E., Lacerte, A., Lee, E. H., Krystal, G., Ali, S., et al. (2002). Activin/TGF-β induce apoptosis through SMAD-dependent expression of the lipid phosphatase ship. Nature Cell Biology, 4(12), 963–969.PubMed
54.
Latres, E., Malumbres, M., Sotillo, R., Martin, J., Ortega, S., Martin-Caballero, J., et al. (2000). Limited overlapping roles of P15(Ink4b) and P18(Ink4c) cell cycle inhibitors in proliferation and tumorigenesis. The EMBO Journal, 19(13), 3496–3506.PubMed
55.
Gomis, R. R., Alarcon, C., Nadal, C., Van Poznak, C., & Massagué, J. (2006). C/EBPβ at the core of the TGF-β cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell, 10(3), 203–214.PubMed
56.
Fong, S., Itahana, Y., Sumida, T., Singh, J., Coppe, J. P., Liu, Y., et al. (2003). Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(23), 13543–13548.PubMed
57.
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., et al. (2009). A mutant-P53/SMAD complex opposes P63 to empower TGF-β -induced metastasis. Cell, 137(1), 87–98.PubMed
58.
Grainger, D. J., Heathcote, K., Chiano, M., Snieder, H., Kemp, P. R., Metcalfe, J. C., et al. (1999). Genetic control of the circulating concentration of transforming growth factor type β1. Human Molecular Genetics, 8(1), 93–97.PubMed
59.
Yokota, M., Ichihara, S., Lin, T. L., Nakashima, N., & Yamada, Y. (2000). Association of a T29→C polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation, 101(24), 2783–2787.PubMed
60.
Ziv, E., Cauley, J., Morin, P. A., Saiz, R., & Browner, W. S. (2001). Association between the T29→C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: the study of osteoporotic fractures. Journal of the American Medical Association, 285(22), 2859–2863.PubMed
61.
Dunning, A. M., Ellis, P. D., McBride, S., Kirschenlohr, H. L., Healey, C. S., Kemp, P. R., et al. (2003). A transforming growth factor β1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Research, 63(10), 2610–2615.PubMed
62.
Hishida, A., Iwata, H., Hamajima, N., Matsuo, K., Mizutani, M., Iwase, T., et al. (2003). Transforming growth factor B1 T29c polymorphism and breast cancer risk in Japanese women. Breast Cancer, 10(1), 63–69.PubMed
63.
Gobbi, H., Dupont, W. D., Simpson, J. F., Plummer, W. D., Jr., Schuyler, P. A., Olson, S. J., et al. (1999). Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. Journal of the National Cancer Institute, 91(24), 2096–2101.PubMed
64.
de Jong, J. S., van Diest, P. J., van der Valk, P., & Baak, J. P. (1998). Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. The Journal of Pathology, 184(1), 44–52.PubMed
65.
de Jong, J. S., van Diest, P. J., van der Valk, P., & Baak, J. P. (1998). Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. The Journal of pathology, 184(1), 53–57.PubMed
66.
Barlow, J., Yandell, D., Weaver, D., Casey, T., & Plaut, K. (2003). Higher stromal expression of transforming growth factor-β type II receptors is associated with poorer prognosis breast tumors. Breast Cancer Research and Treatment, 79(2), 149–159.PubMed
67.
Bacman, D., Merkel, S., Croner, R., Papadopoulos, T., Brueckl, W., & Dimmler, A. (2007). TGF-β receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-β1 expression in colon carcinoma: a retrospective study. BMC Cancer, 7, 156.PubMed
68.
Tsushima, H., Kawata, S., Tamura, S., Ito, N., Shirai, Y., Kiso, S., et al. (1996). High levels of transforming growth factor β 1 in patients with colorectal cancer: association with disease progression. Gastroenterology, 110(2), 375–382.PubMed
69.
Friedman, E., Gold, L. I., Klimstra, D., Zeng, Z. S., Winawer, S., & Cohen, A. (1995). High levels of transforming growth factor β 1 correlate with disease progression in human colon cancer. Cancer Epidemiology, Biomarkers & Prevention, 4(5), 549–554.
70.
Robson, H., Anderson, E., James, R. D., & Schofield, P. F. (1996). Transforming growth factor β 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. British Journal of Cancer, 74(5), 753–758.PubMed
71.
Wikstrom, P., Stattin, P., Franck-Lissbrant, I., Damber, J. E., & Bergh, A. (1998). Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. The Prostate, 37(1), 19–29.PubMed
72.
Diener, K. R., Need, E. F., Buchanan, G., & Hayball, J. D. (2010). TGF-β signalling and immunity in prostate tumourigenesis. Expert Opinion on Therapeutic Targets, 14(2), 179–192.PubMed
73.
Bierie, B., & Moses, H. L. (2006). TGF-β and cancer. Cytokine & Growth Factor Reviews, 17(1–2), 29–40.
74.
Biswas, S., Trobridge, P., Romero-Gallo, J., Billheimer, D., Myeroff, L. L., Willson, J. K., et al. (2008). Mutational inactivation of TGFβR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor β resistant cells. Genes, Chromosomes & Cancer, 47(2), 95–106.
75.
Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J. D., et al. (1999). Mutational inactivation of transforming growth factor β receptor type Ii in microsatellite stable colon cancers. Cancer Research, 59(2), 320–324.PubMed
76.
Akhurst, R. J., & Derynck, R. (2001). TGF-β signaling in cancer—a double-edged sword. Trends in Cell Biology, 11(11), S44–S51.PubMed
77.
Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W., et al. (1995). Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Research, 55(23), 5548–5550.PubMed
78.
Shima, K., Morikawa, T., Yamauchi, M., Kuchiba, A., Imamura, Y., Liao, X., et al. (2011). TGRβR2 and bax mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One, 6(9), e25062.PubMed
79.
Lucke, C. D., Philpott, A., Metcalfe, J. C., Thompson, A. M., Hughes-Davies, L., Kemp, P. R., et al. (2001). Inhibiting mutations in the transforming growth factor β type 2 receptor in recurrent human breast cancer. Cancer Research, 61(2), 482–485.PubMed
80.
Antony, M. L., Nair, R., Sebastian, P., & Karunagaran, D. (2010). Changes in expression, and/or mutations in TGF-β receptors (TGF-βRI and TGF-βRII) and SMAD 4 in human ovarian tumors. Journal of Cancer Research and Clinical Oncology, 136(3), 351–361.PubMed
81.
Scollen, S., Luccarini, C., Baynes, C., Driver, K., Humphreys, M. K., Garcia-Closas, M., et al. (2011). TGF-β signaling pathway and breast cancer susceptibility. Cancer Epidemiology, Biomarkers & Prevention, 20(6), 1112–1119.
82.
Bellam, N., & Pasche, B. (2010). TGF-β signaling alterations and colon cancer. Cancer Treatment and Research, 155, 85–103.PubMed
83.
Yang, G., & Yang, X. (2010). SMAD4-mediated TGF-β signaling in tumorigenesis. International Journal of Biological Sciences, 6(1), 1–8.PubMed
84.
Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., et al. (1996). Dpc4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271(5247), 350–353.PubMed
85.
Kretzschmar, M. (2000). Transforming growth factor-β and breast cancer: transforming growth factor-β/SMAD signaling defects and cancer. Breast Cancer Research, 2(2), 107–115.PubMed
86.
Tram, E., Ibrahim-Zada, I., Briollais, L., Knight, J. A., Andrulis, I. L., & Ozcelik, H. (2011). Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario Site of the Breast Cancer Family Registry (CFR). Breast Cancer Research, 13(4), R77.PubMed
87.
Ashktorab, H., Schaffer, A. A., Daremipouran, M., Smoot, D. T., Lee, E., & Brim, H. (2010). Distinct genetic alterations in colorectal cancer. PLoS One, 5(1), e8879.PubMed
88.
Shao, Y., Zhang, J., Zhang, R., Wan, J., Zhang, W., & Yu, B. (2012). Examination of SMAD2 and SMAD4 copy-number variations in skin cancers. Clinical & Translational Oncology, 14(2), 138–142.
89.
Xu, G., Chakraborty, C., & Lala, P. K. (2003). Reconstitution of SMAD3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells. Biochemical and Biophysical Research Communications, 300(2), 383–390.PubMed
90.
Han, S. U., Kim, H. T., Seong, D. H., Kim, Y. S., Park, Y. S., Bang, Y. J., et al. (2004). Loss of the SMAD3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene, 23(7), 1333–1341.PubMed
91.
Walker, L. C., Fredericksen, Z. S., Wang, X., Tarrell, R., Pankratz, V. S., Lindor, N. M., et al. (2010). Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research: BCR, 12(6), R102.PubMed
92.
Arany, P. R., Flanders, K. C., DeGraff, W., Cook, J., Mitchell, J. B., & Roberts, A. B. (2007). Absence of SMAD3 confers radioprotection through modulation of Erk-Mapk in primary dermal fibroblasts. Journal of Dermatological Science, 48(1), 35–42.PubMed
93.
Samanta, D., Gonzalez, A. L., Nagathihalli, N., Ye, F., Carbone, D. P., & Datta, P. K. (2012). Smoking attenuates transforming growth factor-β-mediated tumor suppression function through downregulation of SMAD3 in lung cancer. Cancer Prevention Research, 5, 452–463.
94.
95.
Tian, F., Byfield, S. D., Parks, W. T., Yoo, S., Felici, A., Tang, B. W., et al. (2003). Reduction in SMAD2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Research, 63(23), 8284–8292.PubMed
96.
Xu, J., Lamouille, S., & Derynck, R. (2009). TGF-β -induced epithelial to mesenchymal transition. Cell Research, 19(2), 156–172.PubMed
97.
Miyazono, K. (2009). Transforming growth factor-β signaling in epithelial–mesenchymal transition and progression of cancer. Proceedings of the Japan Academy, 85(8), 314–323.
98.
Kimelman, D., & Kirschner, M. (1987). Synergistic induction of mesoderm by FGF and TGF-β and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell, 51(5), 869–877.PubMed
99.
Thiery, J. P. (2003). Epithelial–mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology, 15(6), 740–746.PubMed
100.
Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29(34), 4741–4751.PubMed
101.
Edme, N., Downward, J., Thiery, J. P., & Boyer, B. (2002). Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. Journal of Cell Science, 115(Pt 12), 2591–2601.PubMed
102.
Horiguchi, K., Shirakihara, T., Nakano, A., Imamura, T., Miyazono, K., & Saitoh, M. (2009). Role of Ras signaling in the induction of snail by transforming growth factor-β. The Journal of Biological Chemistry, 284(1), 245–253.PubMed
103.
Jenndahl, L. E., Isakson, P., & Baeckstrom, D. (2005). C-Erbb2-induced epithelial–mesenchymal transition in mammary epithelial cells is suppressed by cell–cell contact and initiated prior to E-cadherin downregulation. International Journal of Oncology, 27(2), 439–448.PubMed
104.
Moustakas, A., & Heldin, C. H. (2007). Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Science, 98(10), 1512–1520.PubMed
105.
Fuxe, J., Vincent, T., & Garcia de Herreros, A. (2010). Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting SMAD complexes. Cell Cycle, 9(12), 2363–2374.PubMed
106.
Hills, C. E., Siamantouras, E., Smith, S. W., Cockwell, P., Liu, K. K., & Squires, P. E. (2012). TGF-β modulates cell-to-cell communication in early epithelial-to-mesenchymal transition. Diabetologia, 55(3), 812–824.PubMed
107.
Xie, L., Law, B. K., Chytil, A. M., Brown, K. A., Aakre, M. E., & Moses, H. L. (2004). Activation of the Erk pathway is required for TGF-β1-induced EMT in vitro. Neoplasia, 6(5), 603–610.PubMed
108.
Bhowmick, N. A., Zent, R., Ghiassi, M., McDonnell, M., & Moses, H. L. (2001). Integrin β 1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity. The Journal of Biological Chemistry, 276(50), 46707–46713.PubMed
109.
Galliher, A. J., & Schiemann, W. P. (2006). β3 integrin and Src facilitate transforming growth factor-β mediated induction of epithelial–mesenchymal transition in mammary epithelial cells. Breast Cancer Research, 8(4), R42.PubMed
110.
Galliher, A. J., & Schiemann, W. P. (2007). Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Research, 67(8), 3752–3758.PubMed
111.
Wendt, M. K., & Schiemann, W. P. (2009). Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis. Breast Cancer Research, 11(5), R68.PubMed
112.
Wendt, M. K., Smith, J. A., & Schiemann, W. P. (2009). P130cas is required for mammary tumor growth and transforming growth factor-β-mediated metastasis through regulation of SMAD2/3 activity. The Journal of Biological Chemistry, 284(49), 34145–34156.PubMed
113.
Huber, M. A., Azoitei, N., Baumann, B., Grunert, S., Sommer, A., Pehamberger, H., et al. (2004). NF-κB is essential for epithelial–mesenchymal transition and metastasis in a model of breast cancer progression. The Journal of Clinical Investigation, 114(4), 569–581.PubMed
114.
Neil, J. R., Johnson, K. M., Nemenoff, R. A., & Schiemann, W. P. (2008). Cox-2 inactivates SMAD signaling and enhances EMT stimulated by TGF-β through a Pge2-dependent mechanisms. Carcinogenesis, 29(11), 2227–2235.PubMed
115.
Tian, M., & Schiemann, W. P. (2010). PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-β signaling during mammary tumorigenesis. The FASEB Journal, 24(4), 1105–1116.
116.
Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L., & Arteaga, C. L. (2000). Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. The Journal of Biological Chemistry, 275(47), 36803–36810.PubMed
117.
Lamouille, S., & Derynck, R. (2007). Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. The Journal of Cell Biology, 178(3), 437–451.PubMed
118.
Lamouille, S., & Derynck, R. (2011). Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial–mesenchymal transition. Cells, Tissues, Organs, 193(1–2), 8–22.PubMed
119.
Wendt, M. K., Allington, T. M., & Schiemann, W. P. (2009). Mechanisms of the epithelial–mesenchymal transition by TGF-β. Future Oncology, 5(8), 1145–1168.PubMed
120.
Hurd, T. W., Gao, L., Roh, M. H., Macara, I. G., & Margolis, B. (2003). Direct interaction of two polarity complexes implicated in epithelial tight junction assembly. Nature Cell Biology, 5(2), 137–142.PubMed
121.
Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H. R., Zhang, Y., & Wrana, J. L. (2005). Regulation of the polarity protein Par6 by TGF-β receptors controls epithelial cell plasticity. Science, 307(5715), 1603–1609.PubMed
122.
Viloria-Petit, A. M., David, L., Jia, J. Y., Erdemir, T., Bane, A. L., Pinnaduwage, D., et al. (2009). A role for the TGF-β–Par6 polarity pathway in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 106(33), 14028–14033.PubMed
123.
Araki, S., Eitel, J. A., Batuello, C. N., Bijangi-Vishehsaraei, K., Xie, X. J., Danielpour, D., et al. (2010). TGF-β1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. The Journal of Clinical Investigation, 120(1), 290–302.PubMed
124.
Pandey, J., Umphress, S. M., Kang, Y., Angdisen, J., Naumova, A., Mercer, K. L., et al. (2007). Modulation of tumor induction and progression of oncogenic K-Ras-positive tumors in the presence of TGF-β 1 haploinsufficiency. Carcinogenesis, 28(12), 2589–2596.PubMed
125.
Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., et al. (2008). TGF-β primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 133(1), 66–77.PubMed
126.
Greco, C., Forte, L., Erba, P., & Mariani, G. (2011). Bone metastases, general and clinical issues. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 55(4), 337–352.PubMed
127.
Yin, J. J., Pollock, C. B., & Kelly, K. (2005). Mechanisms of cancer metastasis to the bone. Cell Research, 15(1), 57–62.PubMed
128.
Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., et al. (1999). TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. The Journal of Clinical Investigation, 103(2), 197–206.PubMed
129.
Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., et al. (1996). Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. The Journal of Clinical Investigation, 98(7), 1544–1549.PubMed
130.
Kingsley, L. A., Fournier, P. G., Chirgwin, J. M., & Guise, T. A. (2007). Molecular biology of bone metastasis. Molecular Cancer Therapeutics, 6(10), 2609–2617.PubMed
131.
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50–56.PubMed
132.
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537–549.PubMed
133.
Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial–mesenchymal transitions in development and disease. Cell, 139(5), 871–890.PubMed
134.
Soto, A. M., & Sonnenschein, C. (2011). The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology, 33(5), 332–340.
135.
Leight, J. L., Wozniak, M. A., Chen, S., Lynch, M. L., & Chen, C. S. (2012). Matrix rigidity regulates a switch between TGF-β 1-induced apoptosis and epithelial–mesenchymal transition. Molecular Biology of the Cell, 23, 781–791.PubMed
136.
Copple, B. L. (2010). Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-β-dependent mechanisms. Liver International, 30(5), 669–682.PubMed
137.
Guan, F., Schaffer, L., Handa, K., & Hakomori, S. I. (2010). Functional role of gangliotetraosylceramide in epithelial-to-mesenchymal transition process induced by hypoxia and by TGF-β. The FASEB Journal, 24(12), 4889–4903.
138.
Mak, P., Leav, I., Pursell, B., Bae, D., Yang, X., Taglienti, C. A., et al. (2010). ERbβ impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell, 17(4), 319–332.PubMed
139.
Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J. W., Carey, L., et al. (2004). Reconstruction of functionally normal and malignant human breast tissues in mice. Proceedings of the National Academy of Sciences of the United States of America, 101(14), 4966–4971.PubMed
140.
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., et al. (2004). TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303(5659), 848–851.PubMed
141.
Maffini, M. V., Soto, A. M., Calabro, J. M., Ucci, A. A., & Sonnenschein, C. (2004). The stroma as a crucial target in rat mammary gland carcinogenesis. Journal of Cell Science, 117(Pt 8), 1495–1502.PubMed
142.
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews. Cancer, 6(1), 24–37.PubMed
143.
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., et al. (1992). Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature, 359(6397), 693–699.PubMed
144.
Engle, S. J., Ormsby, I., Pawlowski, S., Boivin, G. P., Croft, J., Balish, E., et al. (2002). Elimination of colon cancer in germ-free transforming growth factor β 1-deficient mice. Cancer Research, 62(22), 6362–6366.PubMed
145.
Ewan, K. B., Oketch-Rabah, H. A., Ravani, S. A., Shyamala, G., Moses, H. L., & Barcellos-Hoff, M. H. (2005). Proliferation of estrogen receptor-α-positive mammary epithelial cells is restrained by transforming growth factor-β1 in adult mice. The American Journal of Pathology, 167(2), 409–417.PubMed
146.
Barcellos-Hoff, M. H., & Akhurst, R. J. (2009). Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Research, 11(1), 202.PubMed
147.
Saunier, E. F., & Akhurst, R. J. (2006). TGF-β inhibition for cancer therapy. Current Cancer Drug Targets, 6(7), 565–578.PubMed
148.
Yang, L. (2010). TGF-β and cancer metastasis: an inflammation link. Cancer Metastasis Reviews, 29(2), 263–271.PubMed
149.
Nam, J. S., Terabe, M., Mamura, M., Kang, M. J., Chae, H., Stuelten, C., et al. (2008). An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Research, 68(10), 3835–3843.PubMed
150.
Ohmori, T., Yang, J. L., Price, J. O., & Arteaga, C. L. (1998). Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Experimental Cell Research, 245(2), 350–359.PubMed
151.
Liu, P., Menon, K., Alvarez, E., Lu, K., & Teicher, B. A. (2000). Transforming growth factor-β and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. International Journal of Oncology, 16(3), 599–610.PubMed
152.
Teicher, B. A. (2001). Malignant cells, directors of the malignant process: role of transforming growth factor-β. Cancer Metastasis Reviews, 20(1–2), 133–143.PubMed
153.
Teicher, B. A., Ikebe, M., Ara, G., Keyes, S. R., & Herbst, R. S. (1997). Transforming growth factor-β 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo, 11(6), 463–472.PubMed
154.
Kirshner, J., Jobling, M. F., Pajares, M. J., Ravani, S. A., Glick, A. B., Lavin, M. J., et al. (2006). Inhibition of transforming growth factor-β1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Research, 66(22), 10861–10869.PubMed
155.
Ewan, K. B., Henshall-Powell, R. L., Ravani, S. A., Pajares, M. J., Arteaga, C., Warters, R., et al. (2002). Transforming growth factor-β1 mediates cellular response to DNA damage in situ. Cancer Research, 62(20), 5627–5631.PubMed
156.
Zhang, M., Kleber, S., Rohrich, M., Timke, C., Han, N., Tuettenberg, J., et al. (2011). Blockade of TGF-β signaling by the TGF-β R-I kinase inhibitor Ly2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Research, 71(23), 7155–7167.PubMed
157.
Liu, Y., Kudo, K., Abe, Y., Hu, D. L., Kijima, H., Nakane, A., et al. (2009). Inhibition of transforming growth factor-β, hypoxia-inducible factor-α and vascular endothelial growth factor reduced late rectal injury induced by irradiation. Journal of Radiation Research, 50(3), 233–239.PubMed
158.
Kakeji, Y., Maehara, Y., Ikebe, M., & Teicher, B. A. (1997). Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. International Journal of Radiation Oncology, Biology, Physics, 37(5), 1115–1123.PubMed
159.
Vujaskovic, Z., Marks, L. B., & Anscher, M. S. (2000). The physical parameters and molecular events associated with radiation-induced lung toxicity. Seminars in Radiation Oncology, 10(4), 296–307.PubMed
160.
Hofer, S. O., Molema, G., Hermens, R. A., Wanebo, H. J., Reichner, J. S., & Hoekstra, H. J. (1999). The effect of surgical wounding on tumour development. European Journal of Surgical Oncology, 25(3), 231–243.PubMed
161.
Teicher, B. A., Maehara, Y., Kakeji, Y., Ara, G., Keyes, S. R., Wong, J., et al. (1997). Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. International Journal of Cancer, 71(1), 49–58.
162.
Yamaguchi, K., Takagi, Y., Aoki, S., Futamura, M., & Saji, S. (2000). Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Annals of Surgery, 232(1), 58–65.PubMed
163.
Tsushima, H., Ito, N., Tamura, S., Matsuda, Y., Inada, M., Yabuuchi, I., et al. (2001). Circulating transforming growth factor β 1 as a predictor of liver metastasis after resection in colorectal cancer. Clinical Cancer Research, 7(5), 1258–1262.PubMed
164.
Shim, K. S., Kim, K. H., Han, W. S., & Park, E. B. (1999). Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer, 85(3), 554–561.PubMed
165.
Feltl, D., Zavadova, E., Pala, M., & Hozak, P. (2005). The dynamics of plasma transforming growth factor β 1 (TGF-β1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer. Oral Oncology, 41(2), 208–213.PubMed
166.
Robert, F., Busby, E., Marques, M. B., Reynolds, R. E., & Carey, D. E. (2003). Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer, 42(2), 237–245.PubMed
167.
Dave, H., Shah, M., Trivedi, S., & Shukla, S. (2011). Prognostic utility of circulating transforming growth factor β 1 in breast cancer patients. The International Journal of Biological Markers, 27, 53–59.
168.
Hirohashi, S., & Kanai, Y. (2003). Cell adhesion system and human cancer morphogenesis. Cancer Science, 94(7), 575–581.PubMed
169.
Teicher, B. A., Holden, S. A., Ara, G., & Chen, G. (1996). Transforming growth factor-β in in vivo resistance. Cancer Chemotherapy and Pharmacology, 37(6), 601–609.PubMed
170.
Andarawewa, K. L., Erickson, A. C., Chou, W. S., Costes, S. V., Gascard, P., Mott, J. D., et al. (2007). Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor β induced epithelial to mesenchymal transition. Cancer Research, 67(18), 8662–8670.PubMed
171.
Begg, A. C., Stewart, F. A., & Vens, C. (2011). Strategies to improve radiotherapy with targeted drugs. Nature Reviews. Cancer, 11(4), 239–253.PubMed
172.
Burdak-Rothkamm, S., & Prise, K. M. (2009). New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells. European Journal of Pharmacology, 625(1–3), 151–155.PubMed
173.
Wiegman, E. M., Blaese, M. A., Loeffler, H., Coppes, R. P., & Rodemann, H. P. (2007). TGF-β-1 dependent fast stimulation of ATM and P53 phosphorylation following exposure to ionizing radiation does not involve TGF-β-receptor I signalling. Radiotherapy and Oncology, 83(3), 289–295.PubMed
174.
Bouquet, F., Pal, A., Pilones, K. A., Demaria, S., Hann, B., Akhurst, R. J., et al. (2011). TGF-β 1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clinical Cancer Research, 17(21), 6754–6765.PubMed
175.
Martin, M., Lefaix, J., & Delanian, S. (2000). TGF-β 1 and radiation fibrosis: a master switch and a specific therapeutic target? International Journal of Radiation Oncology, Biology, Physics, 47(2), 277–290.PubMed
176.
Anscher, M. S., Thrasher, B., Rabbani, Z., Teicher, B., & Vujaskovic, Z. (2006). Antitransforming growth factor-β antibody 1d11 ameliorates normal tissue damage caused by high-dose radiation. International Journal of Radiation Oncology, Biology, Physics, 65(3), 876–881.PubMed
177.
Lan, H. Y. (2011). Diverse roles of TGF-β/SMADs in renal fibrosis and inflammation. International Journal of Biological Sciences, 7(7), 1056–1067.PubMed
178.
Kalluri, R., & Neilson, E. G. (2003). Epithelial–mesenchymal transition and its implications for fibrosis. The Journal of Clinical Investigation, 112(12), 1776–1784.PubMed
179.
Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., Carmona, M. A., et al. (2010). TGF-β receptor inhibitors target the CD44(High)/Id1(High) glioma-initiating cell population in human glioblastoma. Cancer Cell, 18(6), 655–668.PubMed
180.
Fransvea, E., Angelotti, U., Antonaci, S., & Giannelli, G. (2008). Blocking transforming growth factor-β up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 47(5), 1557–1566.PubMed
181.
Fu, K., Corbley, M. J., Sun, L., Friedman, J. E., Shan, F., Papadatos, J. L., et al. (2008). Sm16, an orally active TGF-β type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(4), 665–671.PubMed
182.
Wallace, A., Kapoor, V., Sun, J., Mrass, P., Weninger, W., Heitjan, D. F., et al. (2008). Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clinical Cancer Research, 14(12), 3966–3974.PubMed
183.
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., et al. (1996). Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 93(7), 2909–2914.PubMed
184.
Maggard, M., Meng, L., Ke, B., Allen, R., Devgan, L., & Imagawa, D. K. (2001). Antisense TGF-β2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Annals of Surgical Oncology, 8(1), 32–37.PubMed
185.
Olivares, J., Kumar, P., Yu, Y., Maples, P. B., Senzer, N., Bedell, C., et al. (2011). Phase I trial of TGF-β 2 antisense GM-SCF gene-modified autologous tumor cell (Tag) vaccine. Clinical Cancer Research, 17(1), 183–192.PubMed
186.
Lampropoulos, P., Zizi-Sermpetzoglou, A., Rizos, S., Kostakis, A., Nikiteas, N., Papavassiliou, A.G. (2012). Prognostic significance of transforming growth factor β (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer. Tumour Biology. doi:10.​1007/​s13277-012-0333-3.
187.
Matsumura, N., Huang, Z., Mori, S., Baba, T., Fujii, S., Konishi, I., et al. (2011). Epigenetic suppression of the TGF-β pathway revealed by transcriptome profiling in ovarian cancer. Genome Research, 21(1), 74–82.PubMed
188.
Wang, Z., Chen, C., Finger, S. N., Kwajah, S., Jung, M., Schwarz, H., et al. (2009). Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? The European Respiratory Journal, 34(1), 145–155.PubMed
189.
Duenas-Gonzalez, A., Candelaria, M., Perez-Plascencia, C., Perez-Cardenas, E., de la Cruz-Hernandez, E., & Herrera, L. A. (2008). Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treatment Reviews, 34(3), 206–222.PubMed
Metadata
Title
TGF-β signalling and its role in cancer progression and metastasis
Authors
Yvette Drabsch
Peter ten Dijke
Publication date
01-12-2012
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9375-7

Other articles of this Issue 3-4/2012

Cancer and Metastasis Reviews 3-4/2012 Go to the issue

OriginalPaper

Genes associate with abnormal bone cell activity in bone metastasis

NON-THEMATIC REVIEW

Metastatic view of breast cancer

OriginalPaper

The rejuvenated scenario of epithelial–mesenchymal transition (EMT) and cancer metastasis

NON-THEMATIC REVIEW

The role of FOXP3 in the development and metastatic spread of breast cancer

OriginalPaper

Growth factor signaling in metastasis: current understanding and future opportunities

OriginalPaper

Regulation of the metastatic cell phenotype by sialylated glycans
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits